Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls

EBioMedicine(2024)10.1016/j.ebiom.2024.105042Source: DataRank Database

Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls is a research paper published in EBioMedicine (2024). On theSindex it has a DataRank of 0.262. It has been cited 3 times, with 3 citing works in its 1-hop citation network.

N/A

0.262DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access3 citations · 3 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT05381454

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.47)OA: goldTopics (97)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 79%Citation Network 21%

Base Score Contribution

0.208

From this paper's citation signal

Citation Network Contribution

0.0537

From 3 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis
Frontiers in Pharmacology20257 citations52 referencesContributes 0.040
Mitoquinol improves phagocytosis and glycolysis in ethanol-exposed macrophages via HIF-1α-PFKP axis
The Journal of Immunology20253 citations78 referencesContributes 0.018
Acute pancreatitis: mechanisms and therapeutic approaches
Signal Transduction and Targeted Therapy202615 citations511 referencesContributes 0.005

Authors (3)

Nicholas Jackson ORCID,Theodoros Kelesidis ORCID,Keren Chen ORCID

Live enrichment

PubMed:38471990 PMC:PMC11026948 OpenAlex:https://openalex.org/W4392637095

Clinical and Translational Science Institute, University of California, Los Angeles

Grant: UL1TR001881

California HIV/AIDS Research Program

Grant: OS17-LA-002

National Institutes of Health

Grant: R01AG059502 04S1

National Institutes of Health

Grant: R01AG059501

NIA NIH HHS

Grant: R43 AG059501

NIA NIH HHS

Grant: R01 AG059502

NIAID NIH HHS

Grant: R21 AI178632

National Institutes of Health

Grant: 1R43AG059501-01

Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related Tendinopathy

National Institutes of Health

Grant: 1R01AG059502-01

Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV

National Institutes of Health

Grant: 1R13AG013039-01

1995 SUMMER INSTITUTE IN GERIATRIC MEDICINE

National Institutes of Health

Grant: 3UL1TR001881-01S2

UCLA Clinical Translational Science Institute

National Center for Advancing Translational Sciences

FWCI

0.47

Citation Percentile

0.6%

Citation Trend

2025

2026

goldLicense: CC BY NC ND

journalhttps://doi.org/10.1016/j.ebiom.2024.105042

publisherhttps://doi.org/10.1016/j.ebiom.2024.105042

publisherhttps://api.elsevier.com/content/article/PII:S235239642400077X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S235239642400077X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38471990

Fields of Study

Pharmacological Receptor Mechanisms and EffectsCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-190303 health sciences03 medical and health sciencesAnimalsFemaleHumansMiceAntiviral AgentsCOVID-19Organophosphorus CompoundsPost-Exposure ProphylaxisSARS-CoV-2Treatment OutcomeUbiquinoneSARS-CoV-2 variants

MeSH Terms

COVID-19SARS-CoV-2AnimalsAntiviral AgentsFemaleHumansOrganophosphorus CompoundsUbiquinoneTreatment OutcomeMicePost-Exposure Prophylaxis

Keywords

MedicineClinical trialClinical endpointRandomized controlled trialSingle CenterInternal medicinePost-exposure prophylaxisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Surrogate endpointPre-exposure prophylaxisCoronavirus disease 2019 (COVID-19)ImmunologyDiseaseMen who have sex with menInfectious disease (medical specialty)Antiviral treatmentClinical TrialsTranslational ResearchMitochondrial AntioxidantsCovid-19Sars-cov-2 InfectionMedicine (General)1117 Public Health and Health Services (for)CoronavirusesEpidemiologyUbiquinoneClinical Research (rcdc)MiceCoronaviruses Therapeutics and Interventions1103 Clinical Sciences (for)Animals (mesh)32 Biomedical and Clinical Sciences (for-2020)Humans (mesh)COVID-19 (mesh)Treatment Outcome (mesh)RMice (mesh)ArticlesInfection (hrcs-hc)Infectious DiseasesTreatment OutcomePublic Health and Health ServicesFemalePost-Exposure Prophylaxis (mesh)InfectionAntiviral Agents (mesh)Clinical SciencesClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Coronaviruses Therapeutics and Interventions (rcdc)SARS-CoV-2 (mesh)Antiviral AgentsEmerging Infectious Diseases (rcdc)Ubiquinone (mesh)R5-920Organophosphorus CompoundsClinical ResearchAnimalsHumans3202 Clinical Sciences (for-2020)Biomedical and Clinical SciencesSARS-CoV-2Coronaviruses (rcdc)Emerging Infectious DiseasesOrganophosphorus Compounds (mesh)Infectious Diseases (rcdc)Female (mesh)4202 Epidemiology (for-2020)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being